Full-Time

Senior Clinical Trial Manager

City Therapeutics

City Therapeutics

51-200 employees

Develops RNAi therapeutics using trigger molecules

Compensation Overview

$164k - $185k/yr

+ Bonus + Equity Compensation

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Requirements
  • Bachelor's degree in a life sciences or healthcare-related discipline (advanced degree a plus)
  • Minimum of 6 years of experience in clinical trial management within biotech or pharmaceutical industry
  • Proven ability to manage vendors and CROs, driving accountability and high-quality deliverables
  • Deep knowledge of clinical trial regulations and guidelines (ICH-GCP, FDA, EMA, etc.)
  • Strong project management skills with a proactive, solutions-oriented mindset
  • Excellent interpersonal, communication, and organizational skills
  • Ability to work independently and collaboratively in a dynamic, cross-functional team environment
  • Willingness to travel up to 15%, including international travel
Responsibilities
  • Lead cross-functional teams throughout the lifecycle of clinical trials, including start-up, execution, and close-out. Serve as the primary contact for study-related activities and updates to internal leadership.
  • Contribute to clinical trial strategy, including protocol input, country and site selection, vendor identification, risk management, and development of study timelines and budgets. Lead or support the development of protocols, amendments, clinical study reports, and related documents.
  • Oversee the development and maintenance of key study documents such as informed consent forms, monitoring plans, submission packages, GDPR compliance materials, and annual reports. Drive vendor and CRO performance through oversight plans, performance tracking, and issue resolution. Foster strong partnerships with investigators, site staff, and external partners.
  • Identify and proactively manage study risks with mitigation strategies and appropriate escalation. Ensure compliance with GCP, SOPs, and regulatory requirements across all operational activities. Champion inspection readiness and support audits and regulatory inspections, including CAPA development.
  • Lead the study-level budgeting and site contracting process, in partnership with legal and finance teams. Monitor vendor performance and review invoices, change orders, and scopes of work to ensure financial accountability.
  • Oversee CRO management of the Trial Master File (TMF), ensuring completeness and quality. Ensure timely and accurate registration and updates in clinical trial registries (e.g., ClinicalTrials.gov).
  • Identify and implement opportunities to improve clinical operations processes and drive efficiency. Contribute to departmental goals and strategic initiatives.

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$135M

Headquarters

Massachusetts

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Biogen CNS partnership yields $16M upfront and $1B milestones.
  • CITY-FXI Phase 1 trial yields data late 2026 for thromboembolism.
  • $135M Series A funds pipeline through 2026 IND cadence.

What critics are saying

  • Alnylam erodes edge with superior GalNAc siRNAs in 12-24 months.
  • Silence SLN360 Phase 2 captures Factor XI market in 18-24 months.
  • Cash burns $135M by mid-2027 without Series B funding.

What makes City Therapeutics unique

  • Next-generation cityRNA triggers enable extra-hepatic tissue targeting beyond liver.
  • Co-founded by Alnylam veterans like John Maraganore for RNAi expertise.
  • Proprietary siRNA engineering expands RNAi to CNS and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at City Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Life Insurance

Disability Insurance

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Company News

Business Wire
Oct 8th, 2024
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer Dr. John Maraganore